Thanks for sharing that. Note especially this line
"Between 1998 and 2015, 204 patients with HR localized prostate cancer…"
In other words, the participants in the study all had early-stage ("localized") prostate cancer, not advanced prostate cancer.
There's also the risk that findings based on data they started collecting almost 30 years ago (before even 1st-gen ARSIs like Zytiga were available) might no longer apply, especially now that we have significantly more-effective modern treatments like the -lutamides, but that's another discussion. 🙂
Thanks for sharing that. Note especially this line
"Between 1998 and 2015, 204 patients with HR localized prostate cancer…"
In other words, the participants in the study all had early-stage ("localized") prostate cancer, not advanced prostate cancer.
There's also the risk that findings based on data they started collecting almost 30 years ago (before even 1st-gen ARSIs like Zytiga were available) might no longer apply, especially now that we have significantly more-effective modern treatments like the -lutamides, but that's another discussion. 🙂
Connect
Connect
Like
Helpful
Hug
Thanks for sharing that. Note especially this line
"Between 1998 and 2015, 204 patients with HR localized prostate cancer…"
In other words, the participants in the study all had early-stage ("localized") prostate cancer, not advanced prostate cancer.
There's also the risk that findings based on data they started collecting almost 30 years ago (before even 1st-gen ARSIs like Zytiga were available) might no longer apply, especially now that we have significantly more-effective modern treatments like the -lutamides, but that's another discussion. 🙂
Thanks for clarifying
-
Like -
Helpful -
Hug
1 Reaction